Akari CEO Says Synthetic Royalties May Be Used To Fund Coversin Trials

 
• By Sten Stovall
  
Ticks
Akari Marching Tick-Derived Coversin To Phase III PNH Trials • Source: Akari Therapeutics PLC
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip